Effects Of Aqueous-Ethanolic Extracts And Fractions Of Moringa Oleifera Lam. Leaf On Diabetic And Metabolic Syndrome Rats by Irfan, Hafiz Muhammad
EFFECTS OF AQUEOUS-ETHANOLIC 
EXTRACTS AND FRACTIONS OF Moringa 
oleifera Lam. LEAF ON DIABETIC AND 
METABOLIC SYNDROME RATS  
 
 
 
 
 
 
 
 
HAFIZ MUHAMMAD IRFAN  
 
 
 
 
 
 
 
 
 
 
 
 
UNIVERSITI SAINS MALAYSIA 
2017 
EFFECTS OF AQUEOUS-ETHANOLIC 
EXTRACTS AND FRACTIONS OF Moringa 
oleifera Lam. LEAF ON DIABETIC AND 
METABOLIC SYNDROME RATS  
 
 
 
 
by 
 
 
 
 
HAFIZ MUHAMMAD IRFAN  
 
 
 
 
 
 
 
 
 
 
Thesis submitted in fulfilment of the requirements 
for the Degree of  
Doctor of Philosophy 
 
 
August 2017 
ii 
 
ACKNOWLEDGEMENT 
 
I would like to start with Allah Subhana-O-Wataallah for the strength, wisdom and 
health He bestowed on me, which has been the guiding, force that has helped me to 
accomplish this phase in my journey of knowledge seeking. 
The period of my studying for this Ph.D degree has given me infinite experiences 
and information, which I believe, will be valuable in my future endeavors and will 
help me significantly to achieve greater heights. A number of individuals have been 
instrumental in my study. 
My enormous gratitude goes to my supervisor Prof. Mohd. Zaini Bin Asmawi for his 
innumerable and countless support in guiding me through this learning process of 
research. Prof. Mohd. Zaini’s influence stretch beyond the confines of academic 
field; the warmness and calm level he develops between him and his students, urging 
to achieve excellence while understanding our limits and leniency beyond our 
expectations are attributes that endears both his students and others towards him. His 
contribution towards my study cannot be overemphasized. 
I am also indebted to my co-supervisors, Dr. Nurzalina Abdul Karim Khan, Prof. 
Amirin Sadikun and Prof. Mohd. Nizam Mordi for their persistent interest in the 
progress of my research and constant encouragement and invaluable advices they 
have offered me. Their readiness to offer any help they can is overwhelming and I 
am grateful for that. 
My thanks go to Dr. Yam Mun Fei for his guidance in the initial stages of my 
candidature. Thank you for the advices and kindness. My appreciation also goes to 
all my lab colleagues; Idris Bello, Anis, Nasiba Usman Salisu, Adlin Yussof, , 
Abdulmunem Bakkouri, Majed Al-mansoubb, Bassel Al-Hindi, Raghdaa Al-zouhri 
and Faramarz for their support during my candidature. 
iii 
 
Last but not the least are the most influential people in my life, my parents (Mr. 
Ghulam Rasul and Mrs. Naziran Begum), for the trouble, patience, encouragement, 
and moral lessons they have attempted an impact on my life cannot be expressed in 
words. Thank you for your guidance throughout my life and may Allah reward you 
with Jannatul Firdaus. I would like to extend my thanks to my wife, Sumaira Sharif, 
My children, Muhammad Abdullah Irfan, Amina, Abdul Rehman and Saira for their 
support and encouragement. This would not have been possible without their 
strength and passion for education and their willingness to make the selfless 
sacrifices needed to complete this degree. I will forever be grateful to them. 
I wish to extend my thank to Prof. Dr. Sajid Bashir, Dean and Chairman, Faculty of 
Pharmacy, University of Sargodha and Prof. Dr. Muhammad Shoaib Akhtar who 
helped a lot with valuable inputs and encouragement in making this Ph.D a tenure 
smooth.  
I would like to acknowledge University of Sargodha, Sargodha, Pakistan for 
providing me faculty development scholarship for Ph.D studies. Many thanks to Mr. 
Mohammad Razak, Science officer, Centre for Drug Research, USM for HPLC 
assistance and Mr. Rosli, School of Pharmaceutical Sciences, USM for his technical 
assistance in experimental work. 
 
 
 
Hafiz Muhammad Irfan 
 
 
 
iv 
 
TABLE OF CONTENTS 
 
ACKNOWLEDGEMENT                                                                                                ii 
TABLE OF CONTENTS                                                                                                 iv 
LIST OF FIGURES                                                                                                         xi 
LIST OF TABLES                                                                                                         xvii 
LIST OF ABBREVIATION                                                                                          xix 
ABSTRAK                                                                                                                     xxii 
ABSTRACT                                                                                                                  xxiv 
 
CHAPTER 1- INTRODUCTION                                                                                    1 
1.1 Drug development                                                                                                   1 
1.2 Advancement in phyto-pharmacological studies                                                    2 
1.3 Prevalence of diabetes mellitus                                                                               2 
1.4 Metabolic syndrome                                                                                                3 
1.5 Diabetes mellitus                                                                                                     4 
 1.5.1  Classification of diabetes mellitus                                                                4 
 1.5.2  Type I diabetes mellitus                                                                                5 
 1.5.3  Type II diabetes mellitus                                                                               5 
1.6 Glucose homeostasis                                                                                               7 
 1.6.1  Carbohydrate metabolism by liver                                                                9 
 1.6.2  Glucose metabolism in intestine                                                                 10 
 1.6.3  Glucose transportation in skeletal muscle                                                   11 
1.7 Hyperlipidemia and diabetes mellitus                                                                   12 
1.8 Geriatric patients and diabetes mellitus                                                                13 
1.9 Monocyte chemoattractant  protein-1 and diabetes mellitus                                 15 
1.10 Chemical induction of diabetes mellitus                                                               16 
v 
 
1.11 Anti-diabetic drugs and their mechanism of action                                              18 
 1.11.1  Sulfonylureas                                                                                            18 
 1.11.2  Biguanides                                                                                                 19 
 1.11.3  Thiazolidinediones                                                                                    19 
 1.11.4  α-glucosidase inhibitors                                                                            21 
 1.11.5  Meglitinides                                                                                              21 
 1.11.6  Dipeptidyl peptidase inhibitors                                                                 22 
 1.11.7  Amylin analogue (Pramlintide)                                                                 22 
1.12 Diabetic patient’s compliance towards herbal medicine                                       23 
1.13 Extraction and activity profiling of plant extracts                                                 23 
1.14 Moringa Oleifera Lam. tree                                                                                  24 
 1.14.1  Locality and habitat                                                                                   24 
 1.14.2  Taxonomy of M. oleifera Lam                                                                  25 
 1.14.3  Therapeutic potential and traditional uses of M. oleifera Lam. tree         26 
 1.14.4  M. oleifera leaf                                                                                          29 
 1.14.5  Nutritional and phytochemical composition                                             29 
 1.14.6  Anti-diabetic review on M. oleifera leaf                                                   31 
1.15 Identification of active herbal constituents                                                           32 
1.16 Chromatographic techniques                                                                                 33 
1.17 Problem statement                                                                                                 34 
CHAPTER 2- MATERIALS AND METHODS                                                          37 
2.1 Apparatus, chemicals, and drugs                                                                           37 
2.2 Preparation of plant extracts                                                                                  39 
2.3 Experimental animals                                                                                            41 
vi 
 
2.4 Blood glucose measurement                                                                                 41 
2.5 Experimental design                                                                                              42 
 2.5.1  Effect of aqueous-ethanolic extracts of M. oleifera on blood                     42        
          glucose level of normal rats 
 2.5.2  Effect of aqueous-ethanolic extracts of M. oleifera on blood                     42 
          glucose level of glucose loaded normal rats (IPGTT) 
 2.5.3  Induction of diabetes in rats                                                                        43 
 2.5.4  Effect of single dose oral administration of M. oleifera                             44      
          aqueous-ethanolic extracts on STZ-induced diabetic rats 
 2.5.5  Effect of daily oral administration of aqueous-ethanolic extracts of          44 
          M. oleifera for 14-days on glucose levels of streptozotocin induced  
          diabetic rats 
2.6 Fractionation of most active extract (95% ethanol)                                              45 
 2.6.1  Effect of single dose M. oleifera fractions 500 mg/kg on                           45 
          blood glucose levels of streptozotocin induced diabetic rats 
 2.6.2  Dose response relationship of a single oral dose of M. oleifera                 46  
          95% ethanol extract on blood glucose level of streptozotocin 
          induced diabetic rats 
 2.6.3  Dose response relationship of daily oral administration of M.  oleifera     46  
          95% ethanol extract for 14-days on blood glucose level of                 
          streptozotocin induced diabetic rats 
 2.6.4  Dose response relationship of daily oral administration of M. oleifera      47 
          95% ethanol extract for 14-days on body weight of streptozotocin 
          induced diabetic rats 
vii 
 
2.7 Biochemical analysis                                                                                             47 
2.8 Phytochemical analysis                                                                                         47 
 2.8.1  Qualitative phytochemical screening of aqueous-ethanolic extracts          48 
           and fractions 
 2.8.2  Measurement of total phenolic contents                                                     48 
 2.8.3  Measurement of total flavonoids contents                                                  49 
 2.8.4  Identification of compounds through thin layer chromatography (TLC)   50 
 2.8.5  Development and validation of HPLC method for identification               50 
          of compounds 
           3.8.5(a)  Quantification of identified compounds                                       51 
           3.8.5(b)  Limit of detection and limit of quantification                              51 
           3.8.5(c)  Linearity                                                                                        53 
           3.8.5(d)  Accuracy and precision                                                                53 
2.9 Determination of mechanism of action                                                                 53 
 2.9.1  In vitro α-amylase inhibitory activity                                                          53 
           2.9.1(a)  Principle                                                                                        53 
           2.9.1(b)  Preparation of reagents                                                                 54 
           2.9.1(c)  α-Amylase assay                                                                           55 
           2.9.1(d)  α-Amylase enzyme kinetics                                                          56 
 2.9.2  In vitro α-glucosidase inhibitory activity                                                    57 
           2.9.2(a)  Principle                                                                                        57 
           2.9.2(b)  Preparation of reagents                                                                 57 
           2.9.2(c)  α-Glucosidase assay                                                                      58 
viii 
 
           2.9.2(d)  α-Glucosidase enzyme kinetics                                                    59 
 2.9.3  Measurement of insulin                                                                               59 
           2.9.3(a)  Principle                                                                                        59 
           2.9.3(b)  Preparation of assay solutions                                                      59 
           2.9.3(c)  Insulin assay                                                                                  61 
 2.9.4  Measurement of MCP-1 level                                                                     61 
           2.9.4(a)  Principle                                                                                        61 
           2.9.4(b)  Preparation of reagents                                                                 62 
           2.9.4(c)  Assay procedure                                                                            62 
 2.9.5  Estimation of glucose uptake by skeletal muscle                                        63 
            2.9.5(a)  Principle                                                                                       63 
            2.9.5(b)  Skeletal muscle assay                                                                  63 
 2.9.6  Measurement of glucose-6-phosphate                                                         64 
            2.9.6(a)  Principle                                                                                       64 
            2.9.6(b)  Preparation of reagents                                                                64 
            2.9.6(c)  G6P assay                                                                                    65 
2.10 Effect of aqueous-ethanolic extracts of M. oleifera on metabolic                        65 
syndrome rats 
 2.10.1  High carbohydrate and high fat diet                                                          65 
 2.10.2  Experimental design                                                                                  66      
2.11 Statistical analysis                                                                                                 67 
CHAPTER 3- RESULTS                                                                                                69 
3.1 Plant extracts and their yields                                                                               69 
3.2 Anti-diabetic studies                                                                                              70 
ix 
 
 3.2.1  Effect of aqueous-ethanolic extracts of M. oleifera on blood                     70 
          glucose level of normal rats 
 3.2.2  Effect of aqueous-ethanolic extracts of M. oleifera on blood                     70  
          glucose level of glucose loaded normal rats 
 3.2.3  Effect of single oral dose of M. oleifera aqueous-ethanolic                       73 
          extracts 1000 mg/kg on STZ-induced diabetic rats 
 3.2.4  Effect of daily oral administration of aqueous-ethanolic extracts of          73  
          M. oleifera 1000 mg/kg for 14-days on blood glucose levels of  
          streptozotocin induced diabetic rats 
 3.2.5  Effect of single dose M. oleifera fractions 500mg/kg on blood                  74 
          glucose levels of STZ-induced diabetic rats 
 3.2.6  Dose response relationship of single oral dose M. oleifera 95%                74 
          ethanol extract on blood glucose levels of STZ-induced diabetic rats 
 3.2.7  Dose response relationship of daily oral administration of M. oleifera      75 
          95% ethanol extract for 14-days on blood glucose level of 
          STZ-induced diabetic rats 
 3.2.8  Effect of 14 days daily oral administration of different doses of                75 
          M. oleifera 95% ethanol extract on plasma lipids of 
          STZ-induced diabetic rats      
3.3 Phytochemistry                                                                                                      82 
 3.3.1  Qualitative phytochemical screening                                                          82 
 3.3.2  Quantitative estimation of phenolic and flavonoid contents                       82 
 3.3.3  Thin layer chromatography                                                                         88 
 3.3.4  HPLC method development and validation                                                90 
x 
 
3.4 Determination of anti-diabetic mechanism of action                                            98  
 3.4.1  In vitro α-amylase inhibitory activity and enzyme kinetics                        98 
 3.4.2  In vitro α-glucosidase inhibitory activity and enzyme kinetics                102 
 3.4.3  Effect of 14 days daily oral administration of 95% M. oleifera ethanol   106 
          extracts on plasma insulin levels of streptozotocin-induced 
          diabetic rats  
 3.4.4  Effect of 14 days daily oral administration of 95% M. oleifera ethanol   106 
          extracts on plasma MCP-1 levels of streptozotocin-induced 
          diabetic rats 
 3.4.5  Effect of M. oleifera ethanol extracts on glucose uptake of tricep           109 
          femoralis and rectus abdominus skeletal muscle 
 3.4.6  Effect of 14 days daily oral administration of  M. oleifera 95%               111 
          ethanol extracts on glucose-6-phosphate level of streptozotocin-induced 
          diabetic rats 
3.5      Effects of M. oleifera aqueous-ethanolic extracts on metabolic syndrome        113 
 rats                
CHAPTER 4- DISCUSSION                                                                                       124 
CHAPTER 5- CONCLUSION                                                                                     147 
REFERENCES                                                                                                              149 
APPENDICES                                                                                                                
LIST OF PUBLICATIONS        
 
 
                                                                                    
xi 
 
LIST OF FIGURES 
                                                                 
  Page 
Figure  1.1 Schematic diagram of insulin release from pancreatic β-cell 7 
Figure  1.2 Effects of insulin on carbohydrate metabolism        8 
Figure  1.3 Glucose transportation in skeletal muscle 12 
Figure  1.4 Scheme diagram showing effects of metformin in liver 14 
Figure  1.5 Monocyte chemoattractant protein-1 and its role in STZ-
induced diabetes mellitus 
16 
Figure  1.6 Pancreatic β-cell death by streptozotocin 17 
Figure  1.7 Schematic diagram of mechanisms of action of anti-diabetic 
drugs                                      
20 
Figure  1.8 M. oleifera Lam. tree, Locality: Centre for Drug Research, 
Universiti Sains Malaysia  
25 
Figure  1.9 M. oleifera Lam. leaf 29 
Figure  3.1 Effect of aqueous-ethanolic extracts of M. oleifera 
(1000mg/kg body weight orally) on blood glucose level in 
normal rats 
71 
Figure  3.2 Effect of aqueous-ethanolic extracts of M. oleifera 
(1000mg/kg body weight orally) on blood glucose level of 
glucose loaded normal rats   
72 
Figure  3.3 Effect of single dose of M. oleifera aqueous-ethanolic 
extracts (1000mg/kg body weight orally) in STZ-induced 
diabetic rats  
  
 76 
xii 
 
Figure  3.4 Effect of daily oral administration of aqueous-ethanolic 
extracts of M. oleifera for 14-days on blood glucose levels of 
streptozotocin-induced diabetic rats  
 77 
Figure  3.5 Effect of single dose oral administration of 500 mg/kg M. 
oleifera fractions on blood glucose levels of streptozotocin-
induced diabetic rats  
 78 
Figure  3.6 Dose response relationship of single oral dose M. oleifera 
95% ethanol extract on blood glucose level of STZ –induced 
diabetic rats 
79 
Figure  3.7 Dose response relationship of daily oral administration of M. 
oleifera 95% ethanol extract for 14-days on blood glucose 
level of STZ –induced diabetic rats 
80 
Figure  3.8 Dose response relationship of daily oral administration of M. 
oleifera 95% ethanol extract for 14-days on plasma lipids of 
STZ –induced diabetic rats 
81 
Figure  3.9 Total phenolic contents of 95% ethanol (95% E), 75% 
ethanol (75% E), 50% ethanol (50% E), 25% ethanol (25% 
E) and water extracts (WE) of M. oleifera    
 84 
Figure  3.10 Total phenolic contents of hexane fraction (HF), chloroform 
fraction (CF), ethyl acetate fraction (EAF), butanol fraction 
(BF) and aqueous fraction (AF) of 95% ethanol extract of M. 
oleifera               
 85 
Figure  3.11 Total flavonoid contents of 95% ethanol (95% E), 75% 
ethanol (75% E), 50% ethanol (50% E), 25% ethanol (25% 
E) and water extracts (WE) of M. oleifera                      
86 
xiii 
 
Figure  3.12   Total flavonoid contents of hexane fraction (HF), chloroform 
fraction (CF), ethyl acetate fraction (EAF), butanol fraction 
(BF) and aqueous fraction (AF) of 95% ethanol extract of M. 
oleifera 
 87 
Figure  3.13 TLC chromatogram view at 254 nm of hexane fraction (HF), 
chloroform fraction (CF), ethyl acetate fraction (EAF), 
butanol fraction (BF) and aqueous fraction (AF) of 95% 
ethanol extract of M. oleifera 
88 
Figure  3.14 TLC chromatogram view at 366 nm of hexane fraction (HF), 
chloroform fraction (CF), ethyl acetate fraction (EAF), 
butanol fraction (BF) and aqueous fraction (AF) of 95% 
ethanol extract of M. oleifera 
89 
Figure  3.15 TLC chromatogram view at 254 nm of 95% ethanol extract 
(EE), butanol fraction (BF) of 95% ethanol extract of 
M.oleifera, quercetin 3-β-D-glucoside, cryptochlorogenic 
acid and kaempferol-3-O-glucoside 
89 
Figure  3.16 TLC chromatogram view at 366 nm of 95% ethanol extract 
(EE), butanol fraction (BF) of 95% ethanol extract of 
M.oleifera, quercetin 3-β-D-glucoside, cryptochlorogenic 
acid and kaempferol-3-O-glucoside 
90 
Figure  3.17 Chemical structures of identified compounds in active 95% 
ethanol extract and butanol fraction of M. oleifera leaf 
 92 
Figure  3.18 HPLC chromatogram of 95% ethanol extract (1000 ppm) of 
M. oleifera showing the peaks of cryptochlorogenic acid, 
quercetin 3-β-D-glucoside and kaempferol-3-O-glucoside 
 93 
xiv 
 
Figure  3.19 HPLC chromatogram of active butanol fraction (1000 ppm) 
of 95% ethanol extract of M. oleifera showing the peaks of 
cryptochlorogenic acid, quercetin 3-β-D-glucoside and 
kaempferol-3-O-glucoside 
 94 
Figure  3.20 HPLC chromatogram of a mixture of standard compounds 
(cryptochlorogenic acid, quercetin 3-β-D-glucoside and 
kaempferol-3-O-glucoside) 
 95 
Figure  3.21 Correlation between concentration and percentage of  α-
amylase inhibition of 95% ethanol extract, butanol fraction 
and marker compounds (quercetin 3-β-D-glucoside, 
kaempferol-3-O-glucoside, cryptochlorogenic acid) M. 
oleifera 
 99 
Figure  3.22 Lineweaver-Burk plot of α-amylase enzyme kinetics, 95% 
ethanol extract and butanol fraction of M. oleifera 
101 
Figure  3.23 Correlation between concentration and percentage of  α-
glucosidase inhibition of 95% ethanol extract, butanol 
fraction and marker compounds (quercetin 3-β-D-glucoside, 
kaempferol-3-O-glucoside, cryptochlorogenic acid) M. 
oleifera 
103 
Figure  3.24 Lineweaver-Burk plot of α-glucosidase enzyme kinetics, 
control, active 95% ethanol extract and butanol fraction of 
M.oleifera 
105 
Figure  3.25 Effect of daily oral treatment for 14 days of various doses 
(1000, 500 & 250 mg/kg) of 95% ethanol extract and its 
butanol fraction on plasma insulin concentration of 
 107 
xv 
 
streptozotocin-induced diabetic rats 
Figure  3.26 Effect of daily oral treatment for 14 days of various doses 
(1000, 500 and 250 mg/kg) of M. oleifera 95% ethanol 
extract and its butanol fraction 500 mg/kg on plasma MCP-1 
level of streptozotocin-induced diabetic rats  
 108 
Figure  3.27 Effect of M. oleifera 95% ethanol extract and butanol 
fraction on glucose uptake by tricep femoralis skeletal 
muscle 
 110 
Figure  3.28 Effect of M. oleifera 95% ethanol extract and butanol 
fraction on glucose uptake by ractus abdominus muscle 
110 
Figure  3.29 Effect of variable doses of M. oleifera 95% ethanol extract 
and butanol fraction for 14-days on plasma glucose-6-
phosphate level 
112 
Figure  3.30 Perirenal and epididymal fat of A) normal rat and B) 
metabolic syndrome rat, Liver of C) normal rat and D) 
metabolic syndrome rat 
119 
Figure  3.31 Effect of 30 days daily oral treatment on perirenal-
retroperitoneal fat of metabolic syndrome rat treated with 
water (A), 95% ethanol extract (B), 50% ethanol extract (C) 
and water extract (D) of M. oleifera 
120 
Figure  3.32 Effect of daily oral administration of aqueous-ethanolic 
extracts of M. oleifera (1000mg/kg body weight) for 30 days 
on blood pressure of metabolic syndrome rats 
121 
Figure  3.33 Effect of high fat diet and 20% fructose in drinking water for 
60 days on plasma MCP-1 of rats 
122 
xvi 
 
Figure  3.34 Effect of daily oral administration of aqueous-ethanolic 
extracts of M. oleifera (1,000 mg/kg body weight) for 30 
days on plasma MCP-1 of metabolic syndrome rats 
122 
Figure  3.35 Effect of single oral administration of water 10 ml/kg 
(MSC), 95% ethanol extract (MS 95% E), 50% ethanol 
extract (MS 50% E) and water extract (MSAE) of M. 
oleifera 1000mg/kg on glucose concentration of metabolic 
syndrome rats  
    123 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xvii 
 
LIST OF TABLES 
 
  Page 
Table  1.1 Traditional uses of M. oleifera tree 28 
Table  2.1 Preparation of different solvents for extraction 40 
Table  2.2 HPLC method development parameters  52 
Table  2.3 Assay scheme for glucose uptake by skeletal muscle 64 
Table  2.4 Composition of normal and high-fat diets 68 
Table  3.1 Percentage yields of different extracts of M. oleifera 69 
Table  3.2 Phytochemical screening of different aqueous-ethanolic 
extracts and fractions of active 95% ethanol extracts 
83 
Table  3.3 Quantification of identified compounds in active 95% ethanol 
extract and butanol fraction 
96 
Table  3.4 Showing linearity, regression values, retention time and 
LOD_LOQ of standards 
96 
Table  3.5 Intra-day (within day) and inter-day (between day) accuracy 
and relative standard deviation (RSD%) of standards 
(Cryptochlorogenic acid, quercetin 3-β-D-glucoside and 
kaempferol-3-O-glucoside).         
97 
Table  3.6 α-Amylase IC50 values of 95% ethanol extract, butanol 
fraction and marker compounds (quercetin 3-β-D-glucoside, 
kaempferol-3-O-glucoside, cryptochlorogenic acid) 
 100 
Table  3.7 α-Glucosidase IC50 values of 95% ethanol extract, butanol 
fraction and marker compounds (quercetin 3-β-D-glucoside, 
kaempferol-3-O-glucoside, cryptochlorogenic acid) 
104 
xviii 
 
Table  3.8 Effect of 60 days high fat diet and 20% fructose in drinking 
water on blood glucose, plasma insulin, HOMA-IR and lipid 
profile  
115 
Table  3.9 Effect of 60 days high fat diet and 20% fructose in drinking 
water on body weight, body length, BMI, liver weight and 
abdominal fat  
116 
Table  3.10 Effect of daily oral administration of aqueous-ethanolic 
extracts of M. oleifera (1000mg/kg body weight) for 30 days 
on blood glucose, plasma insulin, HOMA-IR and lipid profile 
in metabolic syndrome rats 
117 
Table  3.11 Effect of daily oral administration of aqueous-ethanolic 
extracts of M. oleifera (1000 mg/kg body weight) for 30 days 
on body weight, body length, BMI, liver weight and 
abdominal fat in metabolic syndrome rats 
118 
Table  3.12 Average daily consumption of normal matched diet (NMD) 
and high fat diet (HFD) per rat 
121 
Table  3.13 Average daily consumption of high-fat-diet in treated groups 123 
 
 
 
 
 
 
 
xix 
 
LIST OF ABBREVIATIONS 
 
ADA American diabetes association 
AF Aqueous fraction 
AMPK Adenosine monophosphate activated protein kinase 
ANS 3-amino-5-nitro-salicylic acid 
ANOVA Analysis of variance 
ARASC Animal research and service centre 
ATP Adenosine triphosphate 
BF Butanol fraction 
BG Blood glucose 
BGC Blood glucose concentration 
BGL Blood glucose level 
BW Body weight 
CE Capillary electrophoresis 
CF Chloroform fraction 
CHD Coronary heart disease 
CTLC Centrifugally accelerated thin layer chromatography 
DCCC Droplet counters currant chromatography 
DM Diabetes mellitus 
DMSO Dimethyl sulfoxide 
DNS 3,5-dinitro salicylic acid 
DPP-IV Dipeptidyl peptidase-IV 
EE Ethanol extract 
EAF Ethyl acetate fraction 
xx 
 
FBG Fasting blood glucose 
FCR Folin ciocalteu reagent 
GC Gas chromatography 
GIT Gastrointestinal tract 
GLP-1 Glucagon like peptide-1 
GLUT 2 Glucose transporter protein 2 
GLUT 4 Glucose transporter protein 4 
GOD Glucose oxidase 
G6Pase Glucose 6-phosphatase 
GS Glycogen synthase 
GSK-3 Glycogen synthase kinase-3 
GTG Gold thioglucose 
HDL High-density lipoprotein 
HF Hexane fraction 
HFD High fat diet 
HMG-CoA 3-Hydroxy-3-methyl-glutaryl-coenzyme A 
HMP Hexose monophosphate 
HPLC High performance liquid chromatography 
HRP Horse radish peroxidase 
IDDM Insulin dependent diabetes mellitus 
IDF International diabetes federation 
IDFA International diabetes federation atlas 
IDL Intermediate density lipoprotein 
IGT Impaired glucose tolerance 
IPGTT Intraperitoneal glucose tolerance test 
xxi 
 
IRS-1 Insulin receptor substrate-1 
KRB Kreb’s ringer bicarbonate 
LDL Low-density lipoprotein 
LOD Limit of detection 
LOQ Limit of quantification 
mAU Milli absorbance unit 
MBC Minimum bactericidal concentration 
MCP-1 Monocyte chemoattractant protein-1 
MIC Minimum inhibitory concentration 
NCE Novel chemicals entities 
NDC Negative diabetic control 
NDDG National diabetes data group 
NIDDM Non-insulin dependent diabetes mellitus 
PDC Positive diabetic control 
PEPCK Phosphoenol pyruvate carboxykinase 
POD Peroxidase 
PPAR-g Peroxisome proliferator activated receptor-gamma 
ROS Reactive oxygen specie 
RSD Relative standard deviation 
SD Sprague dawley 
TC Total cholesterol 
VLDL Very low-density lipoprotein 
WHO World Health Organization 
 
 
 
xxii 
 
KESAN EKSTRAK AKUEUS-ETANOL DAN FRAKSI DAUN Moringa 
oleifera Lam. TERHADAP TIKUS DIABETIK DAN BERSINDROM 
METABOLIK 
 
ABSTRAK 
 
Kemajuan terkini dalam pemencilan dan pengenal pastian sebatian aktif yang 
ada dalam tumbuhan ubatan telah membawa kapada pendekatan bersasar yang 
berasaskan pemecahan, dalam pencarian bioaktif. Oleh itu, penyelidikan ini telah 
direka bentuk untuk menjalankan kajian berpandukan-aktiviti terhadap tikus diabetik 
bagi menentukan ekstrak paling aktif, pecahan yang aktif dan pengenal pastian bahan 
utama aktif menggunakan ekstrak akueus-etanolik daun Moringa oleifera yang 
berlainan. Ekstrak ini juga telah dinilai pada tikus bersindrom metabolik. Lima 
ekstrak berlainan (95, 75, 50 dan 25% [v/v] etanol dan 100% air) telah diuji secara 
oral dalam tikus Sprague Dawley normoglisemik untuk aktiviti anti-hiperglisemik 
dan tolerans glukosa manakala tikus diabetik teraruh-STZ telah digunakan untuk 
aktiviti anti-hiperglisemik akut dan sub-kronik. Ekstrak paling aktif (95% etanol) 
telah dipecahkan lagi kepada pecahan heksana, kloroform, etil asetat, butanol dan 
akueus, dan disaring untuk aktiviti anti-diabetik dalam tikus diabetik. Ekstrak dan 
pecahan aktif kemudiannya di analisis fitokimia secara kualitatif dan kuantitatif, 
termasuk menggunakan kromatografi lapisan nipis (TLC) dan kromatografi cecair 
berprestasi tinggi (HPLC) bagi mengenal pasti sebatian penanda. Antara semua 
ekstrak dan pecahan, ekstrak etanol 95% pada dos 1,000 mg/kg dan pecahan butanol 
pada dos 500 mg/kg telah didapati paling aktif, menunjukkan penurunan glukosa 
darah yang signifikan selepas satu pemberian tunggal dalam tikus diabetik. Tiada 
aktiviti anti-hiperglisemik yang signifikan, dan tolerans glukosa telah tercerap pada 
xxiii 
 
tikus biasa. Kajian dos-respons sub-kronik telah menunjukkan penurunan glukosa 
darah yang amat signifikan dengan dos 500 dan 1,000 mg/kg sahaja. Kumpulan yang 
terawat juga menunjukkan penurunan jumlah kolesterol, trigliserida, lipoprotin 
ketumpatan-rendah dan plasma MCP-1. Eksperimen in vitro bagi perencatan α-
amilase dan α-glukosidase mencadangkan perencatan bukan-kompetitif dan glukosa 
usus mod campuran masing-masing, dan pengambilan glukosa yang lebih baik oleh 
otot skeletal. Analisis TLC dan HPLC mempamerkan kehadiran asid 
cryptochlorogenic, quercetin 3--D-glucoside  dan kaempferol-3-O-glucoside dalam 
ekstrak dan pecahan aktif. Ekstrak akueus-etanolik (v/v) daun Moringa oleifera juga 
menurunkan secara signifikan glukosa darah berpuase, berat hati, kerintangan 
insulin, BMI, lemak abdominal, plasma MCP-1 dan penambahan berat badan dalam 
tikus bersindrom metabolik. Dapatan kajian menunjukkan bahawa ekstrak etanolik 
95% daun Moringa oleifera mempamerkan aktiviti anti-hiperglisemik melalui 
perencatan glukosa usus, fosforilasi glukosa, pengambilan glukosa oleh otot skeletal 
dan kesan pelindungan melalui pengurangan MCP-1. Tambahan pula, hasil daripada 
kajian sindrom metabolik menunjukkan yang sensitiviti terhadap insulin diperbaiki. 
Kesan-kesan ini boleh dianggap disebabkan oleh asid cryptochlorogenic, quercetin 
3--D-glucoside  dan kaempferol-3-O-glucoside. 
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EFFECTS OF AQUEOUS-ETHANOLIC EXTRACTS AND FRACTIONS OF 
Moringa oleifera Lam. LEAF ON DIABETIC AND METABOLIC 
SYNDROME RATS 
 
 
ABSTRACT 
 
Recent advancements in isolation and identification of active compounds 
present in medicinal plants have culminated in a fractionation-guided targeted 
approach in search of bioactivities. Thus, the present research was designed to 
determine the most active extract, active fraction and to identify active principle 
from Moringa oleifera leaf aqueous-ethanol extracts in diabetic rats. In addition, 
these extracts were also assessed in metabolic syndrome rats. Five different aqueous 
ethanol extracts (95, 75, 50, 25% [v/v] ethanol and 100% water) were orally tested in 
normoglycemic Sprague Dawley rats for anti-hyperglycemic activity and glucose 
tolerance. Rats with streptozotocin-induced diabetes were used to assess acute and 
sub-chronic anti-hyperglycaemic activities. The most active extract (95% ethanol) 
was further fractionated into different polarity solvents of hexane, chloroform, ethyl 
acetate, butanol and aqueous fractions and these fractions were screened for anti-
diabetic activity in diabetic rats. The most active extract and fraction were then 
subjected to qualitative and quantitative phytochemical analyses; thin layer 
chromatography (TLC) and high performance liquid chromatography (HPLC) were 
used in order to identify anti-diabetic compounds. Among all extracts and fractions, 
95% ethanol extract at the dose of 1000 mg/kg and butanol fraction at the dose of 
500 mg/kg were found to be most active, showing significant reduction in blood 
glucose concentration upon single administration in diabetic rats. There was no 
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significant anti-hyperglycemic activity, and glucose tolerance was observed in 
normal rats. The sub-chronic dose response studies exhibited highly significant fall 
in blood glucose at 500 and 1,000 mg/kg doses only. The treated groups also 
exhibited significant reduction in total cholesterol, triglycerides, low-density 
lipoprotein and plasma MCP-1. The in vitro experiments on α-amylase and α-
glucosidase inhibition suggested non-competitive and mixed mode intestinal glucose 
inhibition respectively and significant glucose uptake by skeletal muscle. TLC and 
HPLC analyses identified constituents of cryptochlorogenic acid, quercetin 3-β-D-
glucoside, and kaempferol-3-O-glucoside in the active extract and fraction. M. 
oleifera aqueous-ethanol (v/v) extracts significantly decreased fasting blood glucose, 
liver weight, insulin resistance, body mass index, abdominal fat, plasma MCP-1 and 
body weight gain in metabolic syndrome rats as well. This research findings 
indicated that M. oleifera 95% ethanol extract exhibited anti-hyperglycemic activity 
through intestinal glucose inhibition, phosphorylation of glucose, glucose uptake by 
skeletal muscle and protective effect through reduction of MCP-1. Moreover, the 
results of metabolic syndrome studies indicated that the 95% ethanol (v/v) extract 
also improved insulin sensitivity. Anti-diabetic and metabolic syndrome effects 
might be attributed to the compounds cryptochlorogenic acid, quercetin 3-β-D-
glucoside and kaempferol 3-O-glucoside. 
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CHAPTER 1 
    INTRODUCTION 
1.1 Drug development 
Drug development is a long-term process, which requires huge financial resources. 
The pharmaceutical industries generally spend up to 15 years for a drug to be developed, 
tested, approved by the government authorities, and finally marketed (Principe, 1991). 
Although, they adopt time saving strategy, structurally modifying an existing drug 
instead of screening a new drug molecule. Drugs of plant origins are still used e.g. 
morphine, codeine, atropine, digoxin, digitoxin, vincristine, vinblastine, hyoscyamine, 
hyoscine, pilocarpine, forskolin and codeine. The natural sources are used especially 
when the cost of synthetic drug is exorbitant. Therefore, plant materials are still essential 
raw materials for certain medications (Kadir, 1998; Handa, 2005) and for the preparation 
of traditional medicine extracts.  
Natural products and their derivatives represent more than 50% of all the drugs in 
modern therapeutics. Over the past few decades, researchers have focused on drug 
discovery from botanical sources; the success rate of developing a new drug from herbs 
might be higher than that from chemical synthesis (Pan et al., 2013). Currently, the 
focus has certainly changed to understand the benefits and risks of commonly used local 
and traditional plants with the aim of contributing to a better and safer uses of such 
resources (Heinrich, 2006; Heinrich et al., 2009). 
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1.2 Advancements in phyto-pharmacological studies 
The recent advancements in phytochemistry and pharmacological studies in terms of 
isolation and characterization have contributed a lot to the knowledge about new 
therapeutically active compounds obtained from natural products (Filho & Yunes, 
1998). These compounds can be used directly as leads for the development of new drugs 
or as pharmacological tools to discover new active compounds that can improve the 
quality of life in chronic diseases (Kaplan & Gottlieb, 1990; Elisabetsky & Costa-
Campos, 1996). However, it is important to identify active compounds with desired 
biological activity and to determine its correct use regarding dose and route of 
administration (Secco, 1990).  
It is widely accepted that more than 80% of drug substances are either directly 
derived from natural products (Maridass & de Britto, 2008) or isolated from herbs/plants 
for determination of mechanism of action (Krief et al., 2004).    
1.3 Prevalence of diabetes mellitus  
Diabetes mellitus has now become an epidemic, having worldwide incidence of 5% 
in general population (Sangeeta et al., 2010). According to Shaw et al. (2010), there is a 
69% increase in numbers of adults with diabetes in developing countries and a 20% 
increase in developed countries. Not recent any more, the International Diabetes 
Federation (IDF) estimated that in 2011 there were 366 million people with diabetes 
and this was expected to rise to 552 million by 2030 (Whiting et al., 2011). According 
to World Health Organization (WHO), the prevalence of diabetes is now likely to 
increase by 35% and it is expected to be 592 million in the year 2035, with the greatest 
increase expected in low and middle-income developing countries [International 
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diabetes federation atlas (IDFA), 2013]. According to the Malaysian National morbidity 
survey III, the overall prevalence of diabetes mellitus in Malaysia was 11.6% in 2006 
(Letchuman et al., 2010), but has now increased by two fold among Malaysians aged 
≥ 30 years to 22.6%. The prevalence amongst Indians and Malays were 37.9 % and 
23.8% respectively (Nazaimoon et al., 2013). According to the International Diabetes 
Institute, Malaysia has the 4th highest prevalence of diabetics and the most over-weight 
and obese people in Asia. 54% of the adult population is either obese or overweight. As 
a result, 7 out of 10 Malaysian adults suffer from chronic diseases (Ujang, 2013). 
1.4 Metabolic syndrome 
Metabolic syndrome is associated with obesity, insulin resistance, hyperinsulinemia, 
hyperlipidaemia, hyperglycemia, hypertension, fatty liver and impaired energy 
metabolism. Progression may provoke diabetic and cardiovascular complications such as 
congestive heart failure, ventricular hypertrophy. Recently, it has acquired more 
attention worldwide by the physicians and researchers due to its morbidity and mortality 
factors. Metabolic syndrome can be developed in rodents through high-fat diet and 
carbohydrate consumption (Angelova & Boyadjiev, 2013; Mamikutty et al., 2014; 
Grundy et al., 2004). Among carbohydrate, usually D-fructose is preferred as its high 
plasma level is unable to stimulate the release of insulin from the β-cells of pancreas 
(Bray et al., 2004). Now-a-days, traditional medicines have gained wide acceptability 
among general population due to its ease of excess and cost effectivenss (Gurrola-Diaz 
et al., 2010).  
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1.5 Diabetes mellitus 
Diabetes mellitus is a heterogeneous assembly of syndromes, with persistent high 
blood glucose level due to change in various metabolic processes like glycolysis, Krebs 
cycle, gluconeogenesis, hexose monophosphate shunt pathway, glycogenesis and 
glycogenolysis, cholesterol synthesis, synthesis and release of insulin (Prabhakar & 
Doble, 2008).  
According to WHO, it is a chronic metabolic disorder characterized by common 
features of chronic hyperglycemia with alteration in carbohydrate, fat and protein 
metabolism (Mohan, 2005).   
1.5.1 Classification of diabetes mellitus 
The first real attempt to classify diabetes into (i) asymptomatic diabetes and (ii) 
clinical diabetes was done in 1964 by World Health Organization Expert Committee. 
Later, (i) juvenile diabetes, (ii) brittle diabetes, (iii) insulin resistant diabetes, (iv) 
gestational diabetes, (v) pancreatic diabetes and (vi) endocrine diabetes were introduced. 
The big breakthrough came, when The National Diabetes Data Group (NDDG) in the 
USA and second report of the WHO Expert Committee on diabetes mellitus presented a 
classification that was accepted worldwide (NDDG, 1979; WHO, 1980). Two main 
classifications were suggested: Type-I, Insulin dependent diabetes mellitus (IDDM) and 
type-II, non-insulin dependent diabetes mellitus (NIDDM). The specific types for type-II 
include genetic defects of β-cell function, genetic defects of insulin action, diseases of 
exocrine pancreas, endocrinopathies, drug/chemical induced and gestational 
hyperglycemia (WHO, 1985). 
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1.5.2 Type I diabetes mellitus 
Insulin-dependent diabetes mellitus (IDDM) is characterized by the absence or 
loss of β-cells from the pancreas and demands daily injections of insulin to prevent 
diabetic ketoacidosis, coma, and death. It may be due to exogenous chemicals from the 
environment or diet and viral infections (Ilarde & Tuck, 1994).  
This can also be due to autoimmune destruction of the β-cells that leads to 
insulin deficiency and results in resistance to insulin action. Deficiency of insulin on 
target tissues is responsible for abnormalities in carbohydrate, fat and protein 
metabolism (Genuth et al., 2003; American Diabetes Association [ADA], 2009). 
1.5.3 Type II Diabetes Mellitus 
Non-insulin-dependent diabetes mellitus (NIDDM) or maturity-onset diabetes 
mellitus occurs largely in older people, e.g. 16.8 % of persons over 65 years of age in the 
United States have NIDDM, and it is often associated with obesity (Ilarde & Tuck, 
1994). It represents a diabetic state in which the β-cells are usually low in number 
relative to α-cells and insulin secretion is usually insufficient to prevent hyperglycemia. 
The basal rate of hepatic glucose production is elevated and glucagon secretion is 
increased. Moreover, the efficiency of glucose uptake by the peripheral tissues is also 
impaired (Porte & Kahn, 1991). The impairment of pancreatic β-cell functions are the 
dependent risk factors while aging, obesity, insufficient energy consumption, alcohol 
drinking, smoking, etc are independent risk factors of type-II diabetes mellitus 
(Ozougwu et al., 2013).  
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In the early stages, type-II diabetes mellitus is associated with chronic hyperglycemia, 
hyperinsulinemia and insulin resistance. Insulin resistance is due to loss of tissue 
sensitivity to insulin and compensatory secretion of the hormone by the β cells. There 
are the causes of insulin resistance: 
1. Obesity 
2.  Excess glucocorticoids e.g Cushing’s syndrome 
3.  Excess growth hormone e.g acromegaly 
4.  Pregnancy (gestational diabetes)  
5.  Polycystic ovary   
6.  Lipodystrophy (lipid accumulation in liver)  
7.  Autoantibodies to the insulin receptor  
8.  Mutations of insulin receptor 
9.  Mutations of the peroxisome proliferators’ activator receptor γ (PPAR γ)  
10.  Mutations responsible for genetic obesity 
11.  Hemochromatosis (iron accumulation) (Guyton & Hall, 2006) 
Glucotoxicity is also the commonly involved mechanisms for insulin resistance 
(Robertson et al., 2004). It arises from excessive glucose uptake by the β cells and 
production of reactive oxygen species (ROS) in the mitochondrial electron transport 
chain (Kaneto et al., 2007). This results in the stimulation of binding to insulin promoter 
and insulin gene transcription (Robertson & Harmon, 2006). 
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1.6 Glucose homeostasis 
Glucose homeostasis reﬂects a balance between glucose production and its 
utilization. Physiologically, this balance is maintained by the level of circulating insulin 
and tissue responsiveness to it (Gerich, 2000). This is also the result of a balance 
between glucose production by the liver, its storage as glycogen and its uptake by 
peripheral tissues like skeletal muscle and adipose tissue. Insulin is a hormone secreted 
by the β-cells of pancreas (Fig. 1.1).  
 
Fig. 1.1 Schematic diagram of insulin release from pancreatic β-cell (adapted from 
Fournel et al., 2016) 
In normal state, it decreases glucose production in the liver, stimulates its uptake 
by skeletal muscle and peripheral tissues, enhances its storage as glycogen in the liver 
and muscles as shown in Fig. 1.2 (Saltiel, 1996) while in case of obesity, the extra 
glucose is converted to triglycerides and stored as lipid droplets in adipocytes. 
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Therefore, insulin deficiency combined with insulin resistance; contribute to a state of 
hyperglycemia (Gonz´ alez et al., 2006; Dashty, 2013). As the blood glucose level rises, 
the osmotic pressure increases the blood volume and urine output. The glucose starts 
appearing in the urine when the level exceeds its renal threshold (180 mg/dl). This result 
in loss of water from the body and patient feels thirsty (International Diabetes 
Federation, 2007).  Other signs and symptoms include polydipsia, weight loss, 
polyphagia, blurred vision, tachycardia and hypotension (Rang et al., 2012). 
Uncontrolled diabetes causes ketoacidosis and nonketotic hyperglycemic coma 
(Tripathi, 2008). 
 
Fig. 1.2 Effects of insulin on carbohydrate metabolism  
The chronic hyperglycemia is also linked with long-term damage or failure of 
various organs like the eyes, kidneys, nerves, heart, and blood vessels. During this 
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asymptomatic period, it is possible to measure plasma glucose in the fasting state or after 
oral glucose load. (ADA, 2009). 
 2-h postload glucose <140 mg/dL (7.8 mmol/L) = normal glucose tolerance 
 2-h postload glucose 140–199 mg/dL (7.8–11.1 mmol/L) = IGT (impaired 
glucose tolerance) 
 2-h postload glucose ≥200 mg/dL (11.1 mmol/L) = provisional diagnosis of 
diabetes 
1.6.1 Carbohydrate metabolism by liver 
Gluconeogenesis is the major metabolic pathway through which the liver 
synthesizes glucose from lactate, glycerol, amino acids and pyruvate. It is mainly 
activated after a fast in normal individuals and in diabetic patients (Watford, 2005), and 
is controlled by three major enzymes namely, phosphoenol pyruvate carboxykinase 
(PEPCK), fructose-1,6-biphosphatase, and glucose-6-phosphatase (G6Pase). Insulin 
normally reduces the activity of these enzymes to help in normalizing blood glucose 
(Puigserver et al., 2003).  
Glucocorticoid excess also promotes stimulation of gluconeogenesis in the liver 
as well as an inhibition of insulin sensitivity both in the liver and in the skeletal muscles. 
This is probably responsible from an impairment of glucose tolerance to an overt 
diabetes mellitus in susceptible patients with Cushing’s syndrome (Pivonello et al., 
2010). 
Glycogenesis is the storage of glycogen in both the liver and skeletal muscle that 
is catalyzed by glycogen synthase (GS). This enzyme is regulated by several 
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transcriptional factors and kinases, the most important one is the glycogen synthase 
kinase-3 (GSK-3). It is expressed in many diseases such as diabetes, cancer, 
inflammation, Alzheimer (Martinez et al., 2002) and phosphorylates/inhibits GS, thus 
decreases glycogen synthesis in liver and muscles (Wang & Roach, 1993).  
1.6.2 Carbohydrate metabolism in intestine 
Dietary carbohydrates are composed of hexoses such as sucrose, lactose, 
galactose, maltose and pentoses such as xylose and arabinose (Rosensweig & Herman, 
1968). The salivary α-amylase starts digestion of food in the mouth, hydrolyses α-1, 4 
linkage of starch, and converts it to maltose. The pancreatic amylase digests 60% of 
starches. Moreover, intestinal epithelial cellular enzymes (α-glucosidases) cause 
degradation of lactose, sucrose (Mac et al., 2008) and maltose to two glucose molecules 
(Franco et al., 2002; Notkins, 2002). The neuronal signals, enterohormones like 
incretins, meal composition and the intestinal normal ﬂora are also involved in glucose 
absorption. The 5C-carbohydrates such as xylulose, arabinose, ribose and ribulose easily 
diffuse into the intestinal absorptive cells and do not need degradation. Absorption of the 
6C-carbohydrates from intestinal epithelium occurs through passive and active transport 
systems. In the passive diffusion, phosphorylation of carbohydrate results in facilitated 
transfer to the circulation while in the active diffusion, it uses sodium/potassium 
(Na+/K+) pump and against the gradient enter into enterocytes together with Na+ ion 
(Stevens et al., 1984).  
The management of diabetes can be achieved by reducing post-prandial 
hyperglycemia by delaying the activities of α-amylase and α-glucosidase, respectively 
(Ali et al., 2006; Bhandari et al., 2008).  
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1.6.3 Glucose transportation in skeletal muscle 
Skeletal muscle is the principal site for postprandial glucose utilization and 
disposal and has a prominent role in energy balance (Zaid et al., 2008). Insulin plays an 
essential role in glucose regulation by promoting the disposal of postprandial glucose 
into the skeletal muscle that constitutes the major portion of peripheral tissue (Goodman 
& Gilman’s, 2006).  Glucose uptake in the skeletal muscle is regulated through 
translocation of glucose transporter 4 (GLUT4) from the endoplasmic reticulum to the 
plasma membrane (Klip & Ishiki, 2005). Thus a defect in glucose transportation by 
transporters results in insulin resistance (Reaven, 1995). Upon binding of insulin, the 
insulin receptors become activated, and this leads to the phosphorylation of the insulin 
receptor substrates (IRS-1) and/or (IRS-2) on tyrosine residues.  In skeletal muscle, IRS-
1 is primarily responsible for inducing glucose uptake. It activates Phosphatidylinositol-
3-kinase (PI-3-kinase), which in turn promotes the activation of downstream targets and 
translocation of GLUT4 from intracellular to cell surface where it facilitates the entry of 
glucose into the cell (Fig. 1.3). In case of type 2 diabetes mellitus, there is impairment in 
the insulin-stimulated translocation of GLUT4 to cell surface and thus leading to defect 
in insulin-stimulated glucose uptake in peripheral tissues like skeletal muscle and fat 
(Roach, 2005; Goodman & Gilman’s, 2006; Harvey et al., 2012; Tripathi, 2008).   
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Fig. 1.3 Glucose transportation in skeletal muscle (adapted from Winder, 2001) 
1.7 Hyperlipidemia and diabetes mellitus 
The main forms of lipids in the body include cholesterol, phospholipids and 
triglycerides. They are involved in a variety of biological processes such as membrane 
formation, intracellular and intercellular signaling, as well as energy storage and 
production. The body derives its lipids from cellular biosynthesis and from nutrition. 
Cellular biosynthesis of lipids is regulated at the transcriptional level by sterol-regulated 
element-binding proteins-1 & 2 that promote the biosynthesis of fatty acids, triglycerides 
and cholesterol (Horton, 2002).   
Intestinal and plasma lipids are transported by lipoproteins particles. 
Lipoproteins vary in density and, depending on their relative contents are identiﬁed as 
chylomicrons, very low density lipoprotein (VLDL), low density lipoprotein (LDL), 
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intermediate density lipoprotein (IDL) and high-density lipoprotein (HDL) (Havel & 
Kane, 2001). Excess circulating free fatty acids deposited in the muscle and liver tissues 
of obese individuals lead to an increase in the level of intracellular triglycerides. These 
triglycerides and products of fatty acid metabolism are potent inhibitors of insulin 
signaling and result in an acquired insulin resistance state. A decrease in the activity of 
key insulin signaling mediates the lipotoxic effects of free fatty acids (Shulman, 2000). 
Overall, 30-40% of patients with diabetes have triglyceride levels > 200 mg/dL, and 
10% have triglycerides > 400 mg/dL (Cowie & Harris, 1995). Anti-diabetic drug 
(metformin) are known to reduce VLDL through activation of adenosine 
monophosphate protein kinase (AMPK) and reduction of sterol regulatory element 
binding protein as shown in Fig. 1.4 (Phielix et al., 2011). 
1.8 Geriatric patients and diabetes mellitus 
The prevalence of diabetes increases with age and up  to  25-30%  of  elderly  
people  suffer  from  this condition and  10-25%  have  impaired  glucose  tolerance 
(Valle et al., 1997). Older adult’s diabetic patients vary in duration of diabetes, degree of 
hyperglycemia, frequency of diabetes-related complications and disease burden (Blaum 
et al., 2010). They are typically at greater risk for development of microvascular 
complications e.g. diabetic retinopathy, nephropathy, and neuropathy (Booth et al., 
2006), premature death, functional disability, and co-existing illnesses such as 
hypertension, coronary heart disease (CHD), and stroke (Schwartz et al., 2002; Songer, 
1995). It has been estimated that the number of people over 65 with diabetes are 
expected to increase by 4.5-fold between 2005 and 2050 (Narayan et al., 2006). The 
elevated rate of impaired glucose metabolism may be due to a complex group of risk 
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factors that contribute to increasing insulin resistance with aging and impaired β-cells 
function (Halter, 2011). Modification in lifestyle can slow down age-related 
hyperglycemia by reducing the demand on functional β-cells. However, loss of β-cells 
function shifts the patient towards insulin therapy (Halter & Merritt-Hackel, 2011). 
Beside this, the use of oral hypoglycemic agents can compensate for worsening 
pancreatic islet function (Lee et al., 2012). 
 
Fig. 1.4 Scheme diagram showing effects of metformin in liver (Adopted from Phielix et 
al., 2011) 
Key: G6P=Glucose-6-phosphate, FAS=Fatty acyl-CoA synthetase, ACC=Acetyl-CoA 
carboxylase, mTORC2=Mammalian target of rapamycin2, SREBP=Sterol regulatory 
element binding protein, PEPCK=Phosphoenol pyruvate carboxykinase, PK=Pyruvate 
kinase. 
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The management of diabetes can also be achieved by reducing post-prandial 
hyperglycemia by delaying the activities of α-amylase and α-glucosidase enzymes which 
are responsible for the digestion of carbohydrates and absorption of glucose in the 
digestive tract, respectively (Ali et al., 2006; Bhandari et al., 2008).    
1.9 Monocyte chemoattractant protein-1 and diabetes mellitus 
Chemokines constitute a family of chemoattractant cytokines that play a major 
role in migrating monocytes, neutrophils, and lymphocytes, as well as in inducing 
chemotaxis through the activation of G-protein-coupled receptors towards site of injury. 
However, chemokines transmit cell signals that generate multiple responses. 
Specifically, alteration of plasma monocyte chemoattractant protein-1 (MCP-1) 
concentration in metabolic disorders and the presence of circulating chemokines 
reservoirs. MCP-1 is one of the key chemokines that regulate migration and infiltration 
of monocytes/macrophages (Rull et al., 2010; Satish et al., 2009). MCP-1 has been 
extensively studied in the etiologies of obesity and diabetes-related diseases. (Panee, 
2012).  Pancreatic β-cells are selectively destroyed during the course of type 1 diabetes 
(Fig. 1.5). In the early stages of the disease, inﬂammatory inﬁltrates of mononuclear 
cells, containing predominantly monocytes and T-cells, are present in the islets 
(insulitis). Chemokines, such as MCP-1, play a key role in the recruitment and activation 
of these immunocytes (Kutlu et al., 2003). 
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Fig. 1.5 Monocyte chemoattractant protein-1 and its role in diabetes mellitus 
1.10 Chemical induction of diabetes mellitus 
Gold thioglucose (GTG), alloxan/ streptozotocin are the chemical compounds 
used to induce diabetes in laboratory animals, which can be either type-I or type-II 
depends upon animal species and route of administration (Etuk, & Muhammed, 2010). 
GTG is not recommended, as 16-20 weeks are required to induce hyperglycemia, 
hyperphagia, obesity and insulin resistance (Le Marchand Brustel, 1999). The alloxan 
exhibits severe hyperglycaemia, glucosuria, hyperlipidaemia, polyphagia, polydypsia 
and diabetic complications. The major disadvantages of alloxan are the fluctuation of the 
glucose values among different doses, incidence of ketosis and reversal of 
hyperglycaemic state due to pancreatic regeneration. For those reasons, it is now 
replaced with streptozotocin for induction of diabetes (Battell et al., 1999; Srinivasan & 
Ramarao, 2007). 
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Streptozotocin (STZ) is produced by Streptomyces achromogenes that has antibacterial 
and diabetogenic properties. Streptozotocin substantially damages predominantly the 
pancreatic β-cells due to the presence of glucose moiety in its molecule. The glucose 
transporter protein 2 (GLUT2) in the plasma membrane of β-cells has higher affinity for 
streptozotocin to transport it into the cell from plasma as compared to other cells (Elsner 
et al., 2007), causing the β-cells to be more susceptible to damage by the drug.  STZ 
major cytotoxic mechanism is DNA alkylation and strand breakage in both bacterial and 
mammalian cells (Fig. 1.6) but mammalian β-cells are less affected due to lower 
expression of GLUT2 transporter proteins (Eleazu et al., 2013). Physico-chemical 
properties indicate that it is N-acetyl glucosamine derivative and crystalline powder, 
which is very soluble in water (Ventura-Sobrevilla et al., 2011). It is stable at pH 7.4 at 
37°C up to 1 hour.  After reconstitution, it should be protected from light and can be 
stored at room temperature up to 12 h but suggested to be used within 10 min (Povoski 
et al., 1993; Sharma et al., 2010; Joo et al., 2010).  
 
Fig. 1.6 Pancreatic β-cell death by streptozotocin (Adopted from Goud et al., 2015) 
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After streptozotocin administration, there is a state of transient hyperglycemia due to 
sudden breakdown of liver glycogen, followed by hypoglycemia that may be lethal, 
succeeded finally by permanent hyperglycemia that ensures at about 10 to 12 hour after 
STZ administration (Joo et al., 2010). 
1.11 Anti-diabetic drugs and their mechanisms of action 
Anti-diabetic drugs (Fig. 1.7) are prescribed to type II diabetic patients that fulfill the 
following criteria (Timby & Smith, 2013) 
1. Fasting blood glucose level less than 200 mg/dL 
2. Insulin requirement of less than 40 units/day 
3. No ketoacidosis 
4. No renal or hepatic disease 
1.11.1 Sulfonylureas 
Sulfonylureas e.g. glibenclamide act primarily by increasing insulin secretion 
and decreasing the secretion of glucagon. The release of insulin from pancreatic beta 
cells takes place through inhibition of ATP sensitive potassium channels in the plasma 
membrane. When sulfonylurea drug binds to its receptors, it closes the potassium 
channels that lead to the β-cell depolarization, influx of calcium and release of insulin 
from the β-cells. The glucagon secretion decreases from alpha cells because of insulin 
release and pancreatic somatostatin secretion. These also increase insulin sensitivity and 
gain in body weight. The most common adverse effects are hypoglycemia, leucopenia, 
thrombocytopenia and skin rashes (Brenner & Stevens, 2012). 
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1.11.2 Biguanides 
Metformin a biguanide exerts its effects primarily by decreasing hepatic glucose 
output mainly through inhibition of gluconeogenesis. It does not increase plasma lactic 
acid levels in healthy people or patients with normal renal functions. The most common 
reported adverse reaction to metformin therapy is gastrointestinal upset e.g. nausea, 
vomiting, anorexia and diarrhea, metallic taste and weight loss. It is generally started in 
low doses 500-850 mg and maximum up to 2,550 mg daily with meal (Bailey & Turner, 
1996; DeFronzo & Goodman, 1995). 
1.11.3 Thiazolidinediones 
Peroxisome proliferator activated receptors (PPARs) are located throughout the 
body in many different tissues, especially in adipose tissues and present mainly as 
PPARα, PPARδ, and PPARγ forms. The PPARγ is the major target site for 
thiazolidinediones (Nathan et al., 2006). These drugs bind with PPARs in the cells and 
result in the transcription of genes, thus stimulate the production of proteins 
(adiponectin) that promote insulin sensitivity and block transcription of insulin 
resistance or inflammatory proteins (Yki-Jarvinen, 2004; Willson et al., 2001; Chinetti 
et al., 2000).  These drugs can produce hepatotoxicity. Therefore, patients should 
undergo hepatic function tests before initiation of these medications and followed by 
regular monitoring when on this medication. Thiazolidinediones also cause bone 
weakness (Schwartz et al., 2006). 
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Fig. 1.7 Schematic diagram of mechanisms of action of anti-diabetic drugs (adapted 
from Pinterest. The World’s catalog of ideas. Pharmacology) 
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1.11.4 α-glucosidase inhibitors 
α-glucosidase inhibitors (e.g. acarbose) are competitive inhibitors of intestinal α-
glucosidases that hydrolyze oligosaccharides, trisaccharides and disaccharides to glucose 
and other monosaccharides in the small intestine and thus delay postprandial glucose 
absorption (Van de Laar, 2008). These agents are available as a first-line treatment in 
patients with slightly increased fasting blood glucose and marked postprandial 
hyperglycemia (Krentz & Bailey, 2005). Derosa et al. (2009) demonstrated that both 
repaglinide and acarbose had a similar effect on reducing postprandial glucose levels. 
Drugs must be taken 15 min before meal and effective in postprandial hyperglycemia. 
The possible adverse effects include abdominal pain, flatulence, diarrhea and 
hypoglycemia (Timby & Smith, 2013). 
1.11.5 Meglitinides 
Meglitinides includes repaglinide and nateglinide that stimulate insulin secretion 
from β–cells (Black et al., 2007). Repaglinide is the first therapeutically available insulin 
nonsulfonylureas secretagog that specifically enhances early-phase prandial insulin 
response by increasing the sensitivity of β-cells under hyperglycemic conditions 
(Raskin, 2008; Johansen & Birkeland, 2007). The in vitro studies indicate that 
repaglinide is five-times more potent than glibenclamide a sulfonylureas in stimulating 
insulin secretion. Experimentally, it was observed that repaglinide promotes insulin 
release from β-cells only in the presence of glucose whereas glibenclamide can stimulate 
insulin secretion in the absence of glucose also (Fuhlendorff et al., 1998). 
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1.11.6 Dipeptidyl peptidase inhibitors 
Dipeptidyl peptidase-IV (DPP-IV) inhibitors act by inhibiting the enzymatic 
degradation of glucagon-like peptide 1 (GLP-1). It is an incretin hormone produced by 
the distal small intestine and released into the bloodstream. This hormone delay gastric 
emptying, suppresses glucagon release and stimulates insulin release, thus limiting 
postprandial hyperglycemia (Ahren et al., 2003). Sitagliptin, linagliptin, saxagliptin 
require only once daily dosing. These drugs are well tolerated and do not cause 
hypoglycemia and gastrointestinal side effects (Brenner & Stevens, 2012). 
Exenatide is a short acting glucagon-like peptide-1 (GLP-1) analogue (Boon et 
al., 2006) that enhances glucose-dependent insulin secretion (mimic the effects of gut 
incretin). It has similar efficacy to bedtime insulin when added to failing oral regimen, 
but considerably more expensive (Irwin & Rippe, 2009; Katzung, 2007). Glucagon-like 
peptide-2 (GLP-2) is also an intestinal secretion which manages intestinal glucose 
transport (Baggio & Drucker, 2004). 
1.11.7 Amylin analogue (pramlintide)  
Amylin (Pramlintide) is a peptide co-secreted with insulin from β-cells. It 
suppresses postprandial glucagon secretion and slows gastric emptying and thus retards 
digestion and absorption. The glycosylated haemoglobin level decreases on average by 
0.1 or to 0.6 mg/dL. If used in combination with insulin, doses should be decreased by 
half or more to avoid the risk of hypoglycemia (Irwin & Rippe, 2009; Madison Clinic, 
2009). 
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1.12 Diabetic patient’s compliance towards herbal medicines 
Many diabetic patients rely on herbal medicines for the management of their 
diseases particularly in under developed subcontinent (Grover et al., 2002). It is 
estimated that about 80% of the population in African and Asian countries depend on 
conventional medicine for treatment (WHO, 2008) and have an ease access to take such 
medications (WHO, 2013). Today’s plant materials have provided the models for 50% 
of Western drugs (Robbers & Tyler, 1996; Hammer & Carson CF Riley, 1999). The 
most important ones are the secondary metabolites, which include alkaloids, phenolic 
compounds, tannins, phytosterols and terpenoids (Bandow et al., 2003). 
1.13 Extraction and activity profiling of plant extracts 
Extraction is the separation of medicinally active portions from crude source by 
using standard procedures e.g. maceration and percolation. The purpose of extraction 
procedures is to obtain the therapeutically desired material and to eliminate unwanted 
material with a selective solvent (Handa, 2005). Polar solvents are frequently employed 
for the recovery of polyphenols from a plant matrix. The most suitable of these solvents 
are hot or cold aqueous mixtures containing ethanol, methanol, acetone and ethyl 
acetate, to extract compounds from various natural sources (Peschel et al., 2006). 
The natural sources (plants, animals and micro-organisms) provide a big source 
for deriving active compounds.  Predominantly,  the  plant  kingdom  offers  a  variety  
of  species act as  remedies  for  several  diseases  in  many  parts  of  the world 
(Duraipandiyan et al., 2006; Grover et al., 2002).  As  stated  by  Newman and Cragg 
(2010)  that natural  products continued  to  play  a  highly  signiﬁcant  role  in the  drug  
discovery  and  development  process.  These  novel  chemicals  entities  (NCE) are  
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secondary  metabolites e.g. alkaloids, terpenoids and phenolic compounds that are 
present in plant extracts. 
An extract that obtained through extraction, may be used as such (as medicinal 
agent) or it can be further processed to isolate individual chemical compounds. The 
basic parameters that influence the quality of an extract are the plant parts used as 
starting material, the solvent used for extraction and the extraction process. However, it 
is not always an easy, to select extracts from primary screens that are likely to contain 
novel compounds. By comparing the types and levels of activities of different extracts, it 
can be possible to predict the best extract that likely contains components with the 
appropriate pharmacological activity (Littleton et al., 2005; Handa, 2005).  
1.14 Moringa oleifera Lam. tree 
1.14.1 Locality and habitat 
Moringa oleifera Lam. belongs to Moringaceae family of perennial angiosperm 
plants, having 12 other species from the family (Olson, 2002) with a single genus family 
of shrubs (Jahn, 1984; Ndabigengesere et al., 1995). All Moringa species are native to 
Asia (India), from where they have been introduced into other warm countries, such as 
Malaysia and other tropical countries (Fig. 1.8). The tree can tolerate temperatures from 
19 to 28 ºC (Karmakar et al., 2010) and a wide range of rainfall annually from 250 mm 
to over 3000 mm (Palada & Changl, 2003).  
